Literature DB >> 18279698

Excitotoxic neuronal death and the pathogenesis of Huntington's disease.

Ana María Estrada Sánchez1, Jana Mejía-Toiber, Lourdes Massieu.   

Abstract

Huntington's disease (HD) is a neurodegenerative hereditary illness originated by the mutation of the gene encoding the huntingtin-protein (htt). Mutated htt (mhtt) is characterized by an increased number of glutamine repeats in the N-terminal end; when 40 or more glutamine residues are present, the disease is manifested. Expression of mhtt leads to the selective death of the medium spiny neurons (MSN) in the neostriatum, resulting in the appearance of generalized involuntary movements, the main phenotypic alteration of HD. The relationship between the expression of mhtt and the death of the MSN is not fully understood. Nonetheless, according to experimental evidence indicating that MSN are selectively vulnerable to the toxicity of glutamate (excitotoxicity) or its analogues, excitotoxic neuronal death is suggested to be involved in neurodegeneration associated with HD. Support for this hypothesis comes from studies in HD postmortem tissue and transgenic mice models, suggesting a correlation between mhtt expression and altered glutamatergic neurotransmission, mainly altered conductance of the N-methyl-D-aspartate (NMDA) glutamate receptor subtype and decreased levels of glutamate transporters. On the other hand, alterations in energy metabolism are well documented in HD patients, which might facilitate excitotoxicity. Throughout this review we will discuss relevant evidence suggesting that altered glutamatergic neurotransmission plays a role in neurodegeneration associated with HD, as well as the possible contribution of deficient energy metabolism to the development of an excitotoxic cell death cascade in MSN. We show data supporting protection by energy substrates against neuronal damage in a rat model combining energy deficit and glutamate toxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18279698     DOI: 10.1016/j.arcmed.2007.11.011

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  70 in total

Review 1.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

2.  Brain metabolite alterations and cognitive dysfunction in early Huntington's disease.

Authors:  Paul G Unschuld; Richard A E Edden; Aaron Carass; Xinyang Liu; Megan Shanahan; Xin Wang; Kenichi Oishi; Jason Brandt; Susan S Bassett; Graham W Redgrave; Russell L Margolis; Peter C M van Zijl; Peter B Barker; Christopher A Ross
Journal:  Mov Disord       Date:  2012-05-30       Impact factor: 10.338

3.  Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity.

Authors:  Craig K Colton; Qiongman Kong; Liching Lai; Michael X Zhu; Kathleen I Seyb; Gregory D Cuny; Jun Xian; Marcie A Glicksman; Chien-Liang Glenn Lin
Journal:  J Biomol Screen       Date:  2010-05-27

4.  Neuroprotection against neonatal hypoxia/ischemia-induced cerebral cell death by prevention of calpain-mediated mGluR1alpha truncation.

Authors:  Miou Zhou; Wei Xu; Guanghong Liao; Xiaoning Bi; Michel Baudry
Journal:  Exp Neurol       Date:  2009-04-15       Impact factor: 5.330

5.  Intrastriatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington's disease.

Authors:  Kyle D Fink; Andrew T Crane; Xavier Lévêque; Dylan J Dues; Lucas D Huffman; Allison C Moore; Darren T Story; Rachel E Dejonge; Aaron Antcliff; Phillip A Starski; Ming Lu; Laurent Lescaudron; Julien Rossignol; Gary L Dunbar
Journal:  Stem Cells Transl Med       Date:  2014-03-21       Impact factor: 6.940

Review 6.  Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy.

Authors:  Ling Liu; Jin-Sha Huang; Chao Han; Guo-Xin Zhang; Xiao-Yun Xu; Yan Shen; Jie Li; Hai-Yang Jiang; Zhi-Cheng Lin; Nian Xiong; Tao Wang
Journal:  Mol Neurobiol       Date:  2015-12-10       Impact factor: 5.590

7.  Developmental regulation and neuroprotective effects of striatal tonic GABAA currents.

Authors:  V Santhakumar; R T Jones; I Mody
Journal:  Neuroscience       Date:  2010-03-03       Impact factor: 3.590

8.  Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.

Authors:  Ana María Estrada-Sánchez; George V Rebec
Journal:  Basal Ganglia       Date:  2012-07-01

9.  TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease.

Authors:  Xiaobei Zhao; Xu-Qiao Chen; Eugene Han; Yue Hu; Paul Paik; Zhiyong Ding; Julia Overman; Alice L Lau; Sarah H Shahmoradian; Wah Chiu; Leslie M Thompson; Chengbiao Wu; William C Mobley
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

10.  Disruption of Rab11 activity in a knock-in mouse model of Huntington's disease.

Authors:  Xueyi Li; Ellen Sapp; Kathryn Chase; Laryssa A Comer-Tierney; Nicholas Masso; Jonathan Alexander; Patrick Reeves; Kimberly B Kegel; Antonio Valencia; Miguel Esteves; Neil Aronin; Marian Difiglia
Journal:  Neurobiol Dis       Date:  2009-08-20       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.